Hot Features
プレミアム
登録して、同じ考えを持つ投資家と議論するためのアクティブなフォーラムで相互作用するためのアクティブなフォーラムに参加してください。
Abivax Achieves Key Milestone in Phase 3 ABTECT Trial Enrollment Phase 3 ABTECT Trial evaluating obefazimod for moderately to severely active ulcerative colitis (“UC”) reaches 1,003 of 1,224...
Abivax Announces a Change to the Composition of its Board of Directors PARIS, France, December 23, 2024, 10:05 PM CEST – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” or the...
Abivax Establishes an At-the-Market (ATM) Program on Nasdaq PARIS, France, November 19, 2024 – 10:30PM CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq - ABVX) (“Abivax” or the...
Abivax presents third quarter 2024 key financial information PARIS, France, November 14, 2024, 10:00 p.m. CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq – ABVX) (“Abivax” or the...
Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax PARIS, France, November 13, 2024, 10:00 pm CET – Abivax SA (Euronext Paris and...
Abivax Congratulates Victor Ambros and Gary Ruvkun on Their Nobel Prize for the Discovery of microRNA and its Role in Post-Transcriptional Gene Regulation PARIS, France, October 7, 2024, 10:00...
Abivax Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn’s Disease PARIS, France, October 3, 2024 – 10:00 p.m. CEST – Abivax SA (Euronext Paris:...
Abivax Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2-Years of Open-Label Maintenance Patients...
Abivax to Present Three Abstracts for Obefazimod in Ulcerative Colitis at the UEG Week 2024 Professor Bruce E. Sands, MD to present oral presentation of Phase 2b, open-label, maintenance efficacy...
Abivax Provides Update on Ulcerative Colitis (UC) Combination Therapy Program Strategy and Announces Early Preclinical Combination Data of Obefazimod and Etrasimod in Inflammatory Bowel Disease...
| 期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.03 | 0.48231511254 | 6.22 | 6.55 | 5.94 | 27253 | 6.13025869 | DE |
| 4 | -0.83 | -11.7231638418 | 7.08 | 7.36 | 5.94 | 30070 | 6.51542697 | DE |
| 12 | -3.65 | -36.8686868687 | 9.9 | 10.12 | 5.94 | 23903 | 7.6281299 | DE |
| 26 | -5.59 | -47.2128378378 | 11.84 | 11.98 | 5.94 | 21875 | 8.8416775 | DE |
| 52 | -4.07 | -39.4379844961 | 10.32 | 15.42 | 5.94 | 23815 | 11.07130554 | DE |
| 156 | -20.35 | -76.5037593985 | 26.6 | 26.8 | 5.6 | 32098 | 11.68670348 | DE |
| 260 | -15.55 | -71.3302752294 | 21.8 | 36.7 | 5.6 | 31856 | 16.38390635 | DE |
vuletini
10分前
carvajal
11分前
capgain
15分前
navycmdr
16分前
Rum_Tequila
16分前
Rum_Tequila
16分前
Stino2
16分前
ksquared
20分前
Stino2
23分前
tw0122
24分前
tw0122
25分前
knrorrel
27分前
Seminole Red
27分前
Seminole Red
28分前
fuagf
32分前
jackson73
33分前
Investor2014
33分前
knrorrel
34分前
ollik78
34分前
jackson73
34分前
jackson73
37分前
fuagf
37分前
bcblbrbm
43分前
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約
